Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ArQule

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

- PMLiVE

Late-stage failure for Merck’s cilengitide in brain cancer

Integrin inhibitor unable to improve overall survival in phase III trials

- PMLiVE

Merck to develop biosimilars with Samsung-Biogen joint venture

Agreement with Samsung Bioepis covers several candidates

- PMLiVE

Mash Health joins Cello Group

Will sit alongside Insight, MSI, CBS, MedErgy and TVE

- PMLiVE

Merck settles Vytorin lawsuit for $688m

Had faced claims it held back negative data from clinical trials

- PMLiVE

Merck & Co extends autoimmune collaboration with Lycera

New deal could be worth more than $300m to the US biopharma company

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

e-Therapeutics raises £40m to support oncology pipeline

Will fund development of ETS2101 for brain cancer and other potential indications

Just Health PR wins Caris Life Sciences brief

Bioscience company to launches its tumour profiling technology in Europe

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

- PMLiVE

Merck blocks Mylan’s generic Zetia and Vytorin after appeal

Keeps patents of cholesterol medicines protected until April 2017

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links